What is Xenetic Biosciences Price-to-Free-Cash-Flow?
As of today (2024-06-11), Xenetic Biosciences's share price is $3.90.
Xenetic Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.72. Hence, Xenetic Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Xenetic Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Xenetic Biosciences's highest Price-to-Free-Cash-Flow Ratio was 1665.46. The lowest was 8.49. And the median was 13.38.
XBIO's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.98 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 26.10% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 48.30% per year.
During the past 13 years, Xenetic Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 62.20% per year. The lowest was -259.90% per year. And the median was 35.85% per year.
Xenetic Biosciences Price-to-Free-Cash-Flow Historical Data
The historical data trend for Xenetic Biosciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenetic Biosciences's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Xenetic Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Price-to-Free-Cash-Flow falls into.
Xenetic Biosciences's Share Price of today is $3.90. Xenetic Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Xenetic Biosciences Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 